Newspaper Publication

Ref: Akums/Exchange/2026-27/62 November 03, 2026 To, To, The Listing Department The Listing Department National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, C-1, Block G, 25th Floor, New Trading Ring, Bandra Kurla Complex, Rotunda Building, Phiroze Jeejeebhoy Bandra (E), Mumbai – 400 051 Towers, Dalal Street, Mumbai – 400 001 Symbol: AKUMS Scrip Code: 544222 Sub: Newspaper Publication Respected Sir/Ma’am, Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith copies of the newspaper advertisements published on November 03, 2026 in the below mentioned newspapers: 1. Financial Express (English Edition) 2. Jansatta (Hindi Edition) The advertisements contain a Quick Response (“QR”) Code enabling direct access to the un- audited (Standalone & Consolidated) Financial Results of Akums Drugs and Pharmaceuticals Limited (“the Company”) for the quarter and half year ended on September 30, 2026, as approved by the Board of Directors at its meeting held on November 02, 2026. A copy of this disclosure is being updated on the website of the Company at www.akums.in This is for your kind information and records. Thanking You Yours Faithfully For Akums Drugs and Pharmaceuticals Limited Dharamvir Malik Company Secretary & Compliance Officer Encl.: As Above TUESDAY, NOVEMBER 3, 2026 WWW.FINANCIALEXPRESS.COM | FINANCIAL EXPRESS Fusion Finance Limited AKUMS DRUGS AND PHARMACEUTICALS LIMITED 4s Fysi 7 TUSION CIN: LBESIOODLISS4PLC061287 ANG Finance CIN: L24239DL2004PLC125888 Registered address: H-1, C Block, Community Centre, Naraina Vihar, New Delhi - 110028 Regd. Office: 304, 3° Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (India) Corporate office: Plot no. 86, Institutional Sector 32, Gurugram, Haryana - 122001 Corporate Office: Akums House, Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-|, Delhi-110083 Contact Person: Vikrant Sadana, Company Secretary and Compliance Officer; Tal.: +91-124-6910500 Akums Phone: +91-11-69041000, Fax: +91-11-27023256, E-mail: akumsho@akums.net, Website: www.akums.in E-mail: companysecretarym@iusionfin.com; Website: wwwfusionfin.com Extract of Unaudited Financial results for the quarter and half year ended September 30, 2026 UNAUDITED (STANDALONE & CONSOLIDATED) FINANCIAL RESULTS (2 in crore unless otherwise stated) Quarter ended Half year ended | Year ended FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026 5. | ee a ta September) June 30, (September | September | September!) March 31, No. | | 30,2026 2026 30,2025 30,2026 | 30,2025 | 2026 The Board of Directors of Akums Drugs and Pharmaceuticals Limited (‘the Company”), ; ; | | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited Audited on recommendation of the audit committee, at its meeting held on November 2, 2026, For les information, 1_| Total Income from Operations 485.61 | 458.17 | 415.79 | 943.78 | 858.07) 1,698.53 approved the Unaudited (Standalone & Consolidated) Financial Results for the Quarter and please scan: 2 | Net Profit/(ioss) for the period (before Tax, | half year ended September 30, 2026. | Exceptional and/or Extraordinary items) 86.46 | 62.41 | (22.14) | 146.89) (114.39) | (62.93) The full Financial Results along with the Limited Review Report are available on the websites . ‘T, 3 | Net Profit/(toss) for the period before tax (after , of the stock exchanges at www.bseindia.com and www.nseindia.com, and also posted on the : | Exceptional and/or Extraordinary items) 86.80 | be.41 | (22.14) | 148.69) (114/39) | (62.93) | website of the Company and can be accessed at www.akums.in/investors/financial-report/. 4 | Net Profit/(loss) for the period after tax (after | Exceptional-and/or Extraordinary items) 46.48 | B2.41 | (22714) | 148.89 | (114.39) | 13.85 | Sd/- [Comprising Profit/(loss) for the period {after tax) . . and Other Comprehensive Income (after tax)] 68.26 59.61 (29:30) j47.87 (119.13) 11.60 Sanjeev Jain Pare Date:$ November 2, 2026 Managij ng Dii rector 8 | (fai ad ce u vp a luE eq u oi fty %S h 10a /r -e eC aa cp hi )t al 161.59 161.56| 13118 161.59 131.18 161.52 Place: Delhi DIN: 00323433 | — 7 | Reserves (excluding Revaluation Reserve) 72.08 | (19.39) | (221 4) | a2 08 | (221.94) | (83.63) 6 | Securities Premium Account 2,380.18 | 2,478.52 | 2,008.98 | 2,380.18 | 2,008.98 | 2,478.04 9 | Net worth 2,613.85 | 2,520.69 1918.22| 2,613.85) 1,918.22) 2,455.93 e e 10 | Paid up Debt Capital / Outstanding Debt 5,936.33/ 5840.34) 4,933.62) 5,936.33) 4,933.62| 5,570.76) rBO 1 ek Lim ited 11 | Outstanding Redeemable Preference Shares | “| “| | | | CIN: L74999DL2006PL.C155233 12 | Debt Equity Ratio 2.27 | 2.32 | 2.57 | 2.27 | 2.57 | 2.27 | Oo , oO mM Regd. Office: Unit No. 501, 5 Floor, Worldmark-4, Asset Area No. LP-IB-04, Gateway District, Aerocity, Earnings Per Share (face value of ® 10/- each) °. Near Indira Gandhi International Airport, New Delhi-110037 9 (not annualised for quarter and half-year ended] Corporate Office: Plot No. 728, Udyog Vihar Phase-V Gurugram-122016, Haryana, India | ita: | | | | | | : ] Tel. No.: +91 124 499 8999, Email: corporatesecretarial@tbo.com, Website: www.tbo.com | 1 Basic: 9.95 | 3.86 | (1.69) | 9.2 2 | (8.97) | 1.0 | 2. Diluted: ae | 3.89 | (1.69) | Of (6.97) 1.01 | STATEMENT OF UNAUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS 14 | Total debts to total assets 0.67 | 0.67 | 0.70 0.67 | 7 0.67 FOR THE QUARTER AND HALF YEAR ENDED ON SEPTEMBER 30, 2026 15 | Net profit/(loss) margin (%) 17.81% | 13.62%) (5.12%)) 15.77%] (13.02%) 0.80% The Board of Directors of the Company, at their meeting held on November 02, 2026, approved 16 Capital Redemption Reserve NA | NA NA | NA | NA | NA the Unaudited Standalone & Consolidated Financial Results (“Financial Results”) of the Company For more lf | Debenture Redemption Reserve NA | NA | NA | NA | NA | NA | for the Quarter and Half Year ended September 30, 2026. information 18 | Debt Service Coverage Ratio MA MA, MA MA MA | MA The Financial Results along with the Limited Review Reports are disseminated on the Stock Exchange please scan: 19 | Interest Service Coverage Ratio NA | NA | NA | NA | NA | NA websites - www.bseindia.com & www.nseindia.com, and are also posted on the Company’s website - N ste a www.tbo.com, which can be accessed by scanning the given Quick Response code. : , y gtneg P l. The above results have been reviewed by Audit committee and approved by Board of Directors at their respective meetings held For and on behalf of the Board of Directors of on November 02, 2026 in accordance with requirement of the Requlation 33 and Requlation 52 read with Regulation 63/2) of the TBO Tek Limited SEB! (Listing Obligations and Disclosure Requirements) Regulations, 2015. The limited review of financial results for the quarter and half year ended September 30, 2026, have been conducted by the Statutory Auditors of the Company Sd/- Sd/- ¢ Theaboveis an extract of the detailed formatof quarter and half year ended results filed with the Stock Exchanges under Regulation Ankush Nijhawan Gaurav Bhatnagar 33 and Regulation 52 read with Regulation 63(2) of the SEB! (Listing Obligations and Disclosure Requirements), Regulations 2015. Date: November 02, 2026 Joint Managing Director Joint Managing Director The full format of the quarter and half year ended financial results are available on the Stock Exchange website's |.e., National Place: Gurugram DIN: 01112570 DIN: 00446482 Stock Exchange (www.enseindia.com) and BSE Limited (wiww.bseindia.com) and can be accessed on the website of the Company Note: The above intimation is in accordance with Regulation 33, read with Regulation 47(1) of the (www. fusionfin.com). SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. 3, For the items referred in Regulation 52 (4) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, the pertinent disclosures have been made to the Stock Exchang [Showing first 8,000 characters — download PDF for full document]